JP2011525181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525181A5 JP2011525181A5 JP2011514778A JP2011514778A JP2011525181A5 JP 2011525181 A5 JP2011525181 A5 JP 2011525181A5 JP 2011514778 A JP2011514778 A JP 2011514778A JP 2011514778 A JP2011514778 A JP 2011514778A JP 2011525181 A5 JP2011525181 A5 JP 2011525181A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- peptide
- cholesterol efflux
- isolated polypeptide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 146
- 102000004196 processed proteins & peptides Human genes 0.000 description 103
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 96
- 229920001184 polypeptide Polymers 0.000 description 79
- 235000012000 cholesterol Nutrition 0.000 description 42
- 238000000034 method Methods 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 23
- 101150092476 ABCA1 gene Proteins 0.000 description 19
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 19
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 19
- 241000124008 Mammalia Species 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 14
- 239000000816 peptidomimetic Substances 0.000 description 14
- -1 t-butoxycarbonyl Chemical group 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108010030416 proteoliposomes Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 1
- CBEFMGJHEKAMNI-UHFFFAOYSA-N 9-oxofluorene-1-carboxylic acid Chemical group C12=CC=CC=C2C(=O)C2=C1C=CC=C2C(=O)O CBEFMGJHEKAMNI-UHFFFAOYSA-N 0.000 description 1
- HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical group C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 description 1
- DNVJGJUGFFYUPT-UHFFFAOYSA-N 9h-fluorene-9-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)C3=CC=CC=C3C2=C1 DNVJGJUGFFYUPT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7370808P | 2008-06-18 | 2008-06-18 | |
| US61/073,708 | 2008-06-18 | ||
| PCT/US2009/047694 WO2009155366A2 (en) | 2008-06-18 | 2009-06-17 | Improved peptide mediators of cholesterol efflux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525181A JP2011525181A (ja) | 2011-09-15 |
| JP2011525181A5 true JP2011525181A5 (enExample) | 2011-10-27 |
Family
ID=41434685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514778A Withdrawn JP2011525181A (ja) | 2008-06-18 | 2009-06-17 | コレステロール流出の改良型ペプチドメディエータ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8415293B2 (enExample) |
| EP (1) | EP2300038A4 (enExample) |
| JP (1) | JP2011525181A (enExample) |
| KR (1) | KR20110043597A (enExample) |
| CN (1) | CN102123722A (enExample) |
| AU (1) | AU2009260024A1 (enExample) |
| BR (1) | BRPI0915422A2 (enExample) |
| CA (1) | CA2727465A1 (enExample) |
| CL (1) | CL2010001445A1 (enExample) |
| IL (1) | IL209868A0 (enExample) |
| MX (1) | MX2010014003A (enExample) |
| PE (1) | PE20110106A1 (enExample) |
| RU (1) | RU2011101536A (enExample) |
| WO (1) | WO2009155366A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011139819A2 (en) * | 2010-04-28 | 2011-11-10 | The Regents Of The University Of California | Creation of oxidation-resistant hdl mimetic peptides |
| CN105050614B (zh) * | 2013-03-15 | 2019-04-05 | 加利福尼亚大学董事会 | 刺激胆固醇流出的具有降低的毒性的肽 |
| MX2016014306A (es) | 2014-05-02 | 2017-06-12 | Cerenis Therapeutics Holding Sa | Marcadores para terapia con lipoproteinas de alta densidad (hdl). |
| US11091529B2 (en) | 2014-09-17 | 2021-08-17 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
| DK3319980T3 (da) * | 2015-07-10 | 2021-11-22 | Peptinovo Biopharma Inc | Formuleringer til forbedring af virkningen af hydrofobe lægemidler |
| EP3464613A4 (en) | 2016-05-31 | 2020-01-08 | Institut de Cardiologie de Montréal | CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN |
| CN110294791B (zh) * | 2019-06-13 | 2023-02-21 | 倪京满 | 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用 |
| CN111848742B (zh) * | 2020-07-23 | 2021-03-23 | 南京医科大学 | 一种多肽及其制药用途 |
| CN112511569B (zh) * | 2021-02-07 | 2021-05-11 | 杭州筋斗腾云科技有限公司 | 网络资源访问请求的处理方法、系统及计算机设备 |
| CN115300609A (zh) * | 2021-05-08 | 2022-11-08 | 西湖大学 | 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691965B2 (en) * | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| CA2672131C (en) | 2006-12-13 | 2016-06-07 | The Regents Of The University Of California | Potent and selective mediators of cholesterol efflux |
-
2009
- 2009-06-17 RU RU2011101536/15A patent/RU2011101536A/ru not_active Application Discontinuation
- 2009-06-17 WO PCT/US2009/047694 patent/WO2009155366A2/en not_active Ceased
- 2009-06-17 MX MX2010014003A patent/MX2010014003A/es not_active Application Discontinuation
- 2009-06-17 PE PE2010001150A patent/PE20110106A1/es not_active Application Discontinuation
- 2009-06-17 CN CN2009801324185A patent/CN102123722A/zh active Pending
- 2009-06-17 BR BRPI0915422A patent/BRPI0915422A2/pt not_active IP Right Cessation
- 2009-06-17 US US12/999,966 patent/US8415293B2/en active Active
- 2009-06-17 AU AU2009260024A patent/AU2009260024A1/en not_active Abandoned
- 2009-06-17 EP EP09767675.3A patent/EP2300038A4/en not_active Withdrawn
- 2009-06-17 KR KR1020117001120A patent/KR20110043597A/ko not_active Withdrawn
- 2009-06-17 CA CA2727465A patent/CA2727465A1/en not_active Abandoned
- 2009-06-17 JP JP2011514778A patent/JP2011525181A/ja not_active Withdrawn
-
2010
- 2010-12-09 IL IL209868A patent/IL209868A0/en unknown
- 2010-12-16 CL CL2010001445A patent/CL2010001445A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525181A5 (enExample) | ||
| US11969456B2 (en) | Lipoprotein complexes and manufacturing and uses thereof | |
| ES2199939T3 (es) | Dimero de variantes moleculares de apolipoproteina y procedimientos para su produccion. | |
| US20160137711A1 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| JPH07507554A (ja) | 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用 | |
| CN1280501A (zh) | 载脂蛋白a－i激动剂及其在异常脂血相关病症的治疗中的应用 | |
| TW201215394A (en) | Tetranectin-apolipoprotein A-I, lipid particles containing it and its use | |
| RU2011101536A (ru) | Усовершенствованные пептидные медиаторы оттока холестерина | |
| JP2010513311A5 (enExample) | ||
| CN101524529A (zh) | HNF4α诱导分化治疗人体恶性实体瘤 | |
| CN1312178C (zh) | 高密度脂蛋白反应性肽 | |
| KR20240153552A (ko) | 치료용 사이토카인 및 방법 | |
| EP1797123B1 (en) | COMPLEMENTARY PEPTIDES FOR ß-AMYLOID 29-42 PEPTIDE | |
| CN117384269A (zh) | 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用 | |
| AU2015271986B2 (en) | Lipoprotein complexes and manufacturing and uses thereof | |
| CN108342405A (zh) | Il21融合蛋白及其制备方法和在制备靶向治疗肿瘤药物中的用途 | |
| WO2011139819A2 (en) | Creation of oxidation-resistant hdl mimetic peptides | |
| Sheluho | Probing the mechanism of proteins that mediate assembly of the mitochondrial ATP synthase | |
| Bielicki et al. | Peptide mediators of cholesterol efflux | |
| HK1198834B (en) | Lipoprotein complexes and manufacturing and uses therof | |
| HK1192266B (en) | Lipoprotein complexes and manufacturing and uses thereof | |
| HK1192266A (en) | Lipoprotein complexes and manufacturing and uses thereof |